CK: Writing original draft, Writing review & editing
In clinical trials, semaglutide has demonstrated cardiovascular benefits in people with type 2 diabetes and established cardiovascular disease
trials assessed 12 mg as the highest maintenance dose [1] [3]
Modelling equations and patient demographic characteristics are shown in the ESM and Table 1, respectively
Cagrilintide is different from a GLP-1 drug and has also shown promise as a weight loss drug along with semaglutide, the active ingredient in popular weight loss drugs like Ozempic and Wegovy, and Novo Nordisk, the maker of Ozempic, has a clinical trial to determine if cagrilintide can be an effective weight loss drug standing alone
Unexplained infertility may be due to increased oxidative stress load and a depleted antioxidant reservoir to combat the toxic effects of oxidative stress